Summary & Overview
HCPCS J9214: Interferon alfa-2b injection, 1 million units
HCPCS Level II code J9214 denotes the injection of recombinant interferon alfa-2b, measured per 1 million units. This drug-class billing code matters nationally because interferon alfa-2b is used in oncology and certain antiviral or immunologic treatments where accurate drug-unit reporting affects clinical documentation, drug inventory management, and payer adjudication. The code is relevant across governmental and commercial payers given its use in hospital outpatient departments, ambulatory infusion centers, and physician offices.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9214 represents clinically and operationally, guidance on where services are typically delivered, and an outline of the payer types that commonly reimburse this injectable biologic. The publication summarizes benchmarking and coverage contexts, highlights coding considerations tied to unit-based billing, and notes typical billing modifiers and settings where this code appears.
This summary is intended for a national audience of billing professionals, practice managers, and policy analysts who need a clear reference on the clinical meaning, service contexts, and payer landscape for HCPCS Level II code J9214. Data not available in the input are identified where applicable.
Billing Code Overview
HCPCS Level II code J9214 represents an injection of interferon alfa-2b, recombinant, in a unit of 1 million units. This code is used to report administration of the specified biologic drug when billed as a drug or biological supply.
-
Service type: Injectable biologic therapy
-
Typical site of service: Ambulatory infusion clinic, physician office, hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic viral infection or a malignancy-related indication being treated with recombinant interferon alfa-2b. The medication J9214 is billed per 1 million units for parenteral administration. A common scenario is a patient with melanoma or select hematologic malignancies receiving planned intramuscular or subcutaneous injections in an outpatient oncology or ambulatory infusion clinic. The clinical workflow: the oncologist or infectious disease specialist prescribes interferon alfa-2b in units; nursing verifies dose, obtains informed consent and allergy history, prepares the injection under aseptic technique, and documents lot number and amount administered. Vitals and brief adverse-effect screening occur pre- and post-injection, with observation for acute reactions. The encounter is coded using J9214 units corresponding to the ordered million-unit increments, with appropriate modifier(s) appended for circumstances such as multiple procedures, unusual circumstances, or supply disposition (e.g., wastage). Typical sites of service are outpatient infusion centers, physician offices, and ambulatory clinics. Typical patients may require serial administrations over weeks to months with documentation of treatment tolerance and response in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |